The five-year survival rate for follicular lymphoma is 80-90% with patients surviving for a median of 10-12 years. Patients with stage I follicular lymphoma may be cured with radiation therapy. The five-year survival rate for follicular lymphoma is between 80 and 90 percent, which means at least 80 to 90 percent of patients diagnosed with...
What is Brukinsa (zanubrutinib), and what is it used for? Brand name: Brukinsa Generic: zanubrutinib Brukinsa (zanubrutinib) is a prescription medicine used to treat the symptoms of mantel cell lymphoma (MCL) and Waldenström macroglobulinemia, both of which are types of non-Hodgkin lymphoma. It is not known if Brukinsa is safe and effective in children. What are...
Chronic lymphocytic leukemia (CLL) is cancer in which the bone marrow (spongy part of the bone) makes abnormal white cells (lymphocytes). According to recent research, the Mediterranean diet is considered the best diet for patients with chronic lymphocytic leukemia (CLL). According to recent research, the Mediterranean diet is considered the best diet for patients with...
Generic drug: osimertinib Brand name: Tagrisso What is Tagrisso (osimertinib), and how does it work? Tagrisso (osimertinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s): to help prevent your lung cancer from coming back after your tumor(s) has been...
Facts you should know about multiple myeloma Picture of Cancer Cell Multiple myeloma is a cancer of the plasma cells in the bone marrow. Seek medical care for unexplained pain, nausea, vomiting, weight loss, vision problems, or chronic tingling or numbness. There is no cure for multiple myeloma. Treatment of multiple myeloma focuses on decreasing...
While NSCLC is the more common type of lung cancer, it is slow-growing and far less aggressive than SCLC. Non-small cell lung cancer (NSCLC) carries a better prognosis than small cell lung cancer (SCLC). NSCLC is slow-growing, whereas SCLC grows far more aggressively. Additionally, NSCLC is the more common type, accounting for 85 percent of...
The lifespan and survival rate of patients diagnosed with stage III lung cancer depends on the type and subtype of the cancerous tumor. Typically, there are four stages for any cancer progression, with each stage representing the extent or spread, number and size of the tumor in the body. After identifying the stage, doctors decide...
NSCLC is slow-growing and less aggressive than SCLC, which means the survival rate and lifespan are better compared to other types of lung cancer. Lung cancer is one of the deadliest forms of cancer with many deaths that surpass the three most common cancers combined (colon, breast and pancreatic). There are two main types of...
While stage IV lung cancer is hard to cure, advancements in cancer treatments may help improve your lifespan and survival rate, depending on your overall state of health. Your doctor is the best person to talk to when it comes to your cancer diagnosis and outlook. Fortunately, cancer research has grown rapidly in the last...
Typically, the survival rate for stage I lung cancer is anywhere from 70 to 92 percent, depending on the type. Early diagnosis and treatment can improve the outlook. Lung cancer, the third most common type of cancer, is the leading cause of cancer-related deaths worldwide. Though it can be fatal, early diagnosis and treatment can...